IL108063A - Use of beta-(l)-5-fluorodideoxycitidine for the preparation of a pharmaceutical composition for the treatment of viral hepatitis b - Google Patents

Use of beta-(l)-5-fluorodideoxycitidine for the preparation of a pharmaceutical composition for the treatment of viral hepatitis b

Info

Publication number
IL108063A
IL108063A IL10806393A IL10806393A IL108063A IL 108063 A IL108063 A IL 108063A IL 10806393 A IL10806393 A IL 10806393A IL 10806393 A IL10806393 A IL 10806393A IL 108063 A IL108063 A IL 108063A
Authority
IL
Israel
Prior art keywords
enantiomer
medicament
use according
treatment
pharmaceutically acceptable
Prior art date
Application number
IL10806393A
Other languages
English (en)
Other versions
IL108063A0 (en
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Publication of IL108063A0 publication Critical patent/IL108063A0/xx
Publication of IL108063A publication Critical patent/IL108063A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL10806393A 1992-12-24 1993-12-17 Use of beta-(l)-5-fluorodideoxycitidine for the preparation of a pharmaceutical composition for the treatment of viral hepatitis b IL108063A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929226927A GB9226927D0 (en) 1992-12-24 1992-12-24 Dideoxy nucleoside analogues

Publications (2)

Publication Number Publication Date
IL108063A0 IL108063A0 (en) 1994-04-12
IL108063A true IL108063A (en) 1999-10-28

Family

ID=10727197

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10806393A IL108063A (en) 1992-12-24 1993-12-17 Use of beta-(l)-5-fluorodideoxycitidine for the preparation of a pharmaceutical composition for the treatment of viral hepatitis b

Country Status (21)

Country Link
US (1) US6156737A (es)
EP (2) EP0765665A1 (es)
JP (2) JP2818299B2 (es)
KR (1) KR100331714B1 (es)
AP (1) AP450A (es)
AT (1) ATE157877T1 (es)
AU (1) AU681370B2 (es)
CA (1) CA2143204C (es)
DE (1) DE69313872T2 (es)
DK (1) DK0675724T3 (es)
ES (1) ES2108969T3 (es)
GB (1) GB9226927D0 (es)
GR (1) GR3024699T3 (es)
HK (1) HK1002426A1 (es)
IL (1) IL108063A (es)
MY (1) MY127808A (es)
NZ (1) NZ259487A (es)
RU (1) RU2160108C2 (es)
SG (1) SG48956A1 (es)
WO (1) WO1994014456A1 (es)
ZA (1) ZA939677B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346627B1 (en) * 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2637774C (en) * 1993-09-10 2011-07-19 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) * 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
WO1996040164A1 (en) 1995-06-07 1996-12-19 Emory University Nucleosides with anti-hepatitis b virus activity
US6100301A (en) * 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
ZA984796B (en) * 1997-06-10 1998-12-29 Chong Kun Dang Corp Novel optically active nucleoside derivative its manufacturing method and anti-HBV composition containing the derivative thereof
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DK224286A (da) * 1985-05-15 1986-11-16 Wellcome Found 2',3'-dideoxy-nucleosider
US4788181A (en) * 1986-09-29 1988-11-29 The United States Of America As Represented By The Department Of Health And Human Services 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity
IL85778A0 (en) * 1987-03-20 1988-09-30 Bristol Myers Co Production of 2',3'-dideoxynucleosides and certain such novel compounds
US5215970A (en) * 1987-04-16 1993-06-01 Medivir Ab Nucleosides and nucleotide analogues, pharmaceutical composition and processes for the preparation of the compounds
CA1327000C (en) * 1987-08-07 1994-02-15 David L.J. Tyrrell Antiviral therapy for hepatitis b
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
AU5659990A (en) * 1989-05-15 1990-12-18 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method of treatment of hepatitis
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
EP1142891B1 (en) * 1991-03-06 2007-05-02 Emory University Salts and amides of (-)cis 5-Fluoro-2'-deoxy-3'-thiacytidine useful for the treatment of hepatitis B
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
JPH09222548A (ja) * 1996-02-19 1997-08-26 Asahi Optical Co Ltd レンズ駆動機構

Also Published As

Publication number Publication date
CA2143204A1 (en) 1994-07-07
DK0675724T3 (da) 1998-03-09
MY127808A (en) 2006-12-29
ES2108969T3 (es) 1998-01-01
RU2160108C2 (ru) 2000-12-10
CA2143204C (en) 1997-06-03
IL108063A0 (en) 1994-04-12
HK1002426A1 (en) 1998-08-21
KR100331714B1 (ko) 2002-11-01
SG48956A1 (en) 1998-05-18
WO1994014456A1 (en) 1994-07-07
ZA939677B (en) 1994-08-26
DE69313872D1 (de) 1997-10-16
GB9226927D0 (en) 1993-02-17
AP450A (en) 1996-01-19
JP2818299B2 (ja) 1998-10-30
NZ259487A (en) 1997-06-24
US6156737A (en) 2000-12-05
DE69313872T2 (de) 1998-01-08
GR3024699T3 (en) 1997-12-31
ATE157877T1 (de) 1997-09-15
AU5830194A (en) 1994-07-19
AU681370B2 (en) 1997-08-28
EP0675724B1 (en) 1997-09-10
EP0765665A1 (en) 1997-04-02
EP0675724A1 (en) 1995-10-11
JPH07509730A (ja) 1995-10-26
AP9300603A0 (en) 1994-01-31
JPH10139668A (ja) 1998-05-26

Similar Documents

Publication Publication Date Title
US6156737A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
EP0526253B1 (en) 1,3-Oxathiolane nucleoside analogues
EP0565549B1 (en) Use of 1,3-oxathiolane nucleoside analogues in the manufacture of a medicament for treatment of hepatitis b
AU715213B2 (en) Synergistic combinations of zidovudine, 1592U89 and 3TC or FTC
US6107288A (en) Antiviral nucleoside combination
EP0639971B1 (en) Therapeutic combinations
NZ314731A (en) Use of dideoxycytosine derivatives in medicaments for treating hepatitis b viral infections

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees